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A burgeoning area of focus within liver disease research is centered on the concomitant 
muscle atrophy present in end stage liver disease patients which shows a correlation to 
severity of hepatic fibrosis and transplant survival outcomes. Of particular interest, 
nonalcoholic steatohepatitis (NASH) is a form of liver disease that is characterized as the 
hepatic manifestation of metabolic syndrome. If left untreated, the disease can progress to 
the state of cirrhosis and hepatocellular carcinoma requiring transplant. Concordant with 
increasing global prevalence of obesity, NASH is projected to become the leading cause 
for liver transplants by 2020. Due to a lack of therapeutic options, these patients represent 
a large unmet medical need in the western world. A major hurdle to therapeutic research 
is the lack of a quick, reproducible, and cost effective in vivo model that recapitulates the 
plethora of pathologies and their molecular underpinnings manifested by this disorder. 
Our studies attempted to validate and expand upon a two-hit model of NASH, which 
incorporated both the integral comorbidities associated with metabolic challenges of 
obesity along with liver injury. The two-hit model manifests not only the hepatic 
morphohistological characteristics of the disease, but also incorporates the obligatory 
muscle atrophy. To further elaborate on the potential direct link between liver and 
skeletal muscle and remove any confounding issues associated with the model, in vitro 
administration of hepatotoxins representing various pathologies associated with liver 
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disease, were used to recapitulate the liver-muscle endocrine signaling that exists in vivo. 
Our data shows that a variety of hepatoxins can elicit hepatocellular damage which 
releases factors that inhibits myotube size in vitro. The two hit model also preserves 
many of conserved molecular underpinnings observed in clinical hepatic fibrosis. Of 
particular interest, the TGFβ superfamily has been demonstrated to play an important 
regulatory role in the progression of fibrosis in NASH patients. TGFβ, Activin A, and 
Follistatin are members of the highly conserved family that are increased in NASH 
patients. Furthermore, these proteins have a well-studied role in muscle health, 
regeneration, and mass that has been hypothesized to be conserved between liver and 
muscle tissues. Surprisingly, novel expression of the myokine and negative regulator of 
muscle mass Gdf8 (myostatin) was increased in our in vivo model as well. Our studies 
focused on the molecular interactions of these TGFβ superfamily members and their role 
on liver disease progression. Through specific inhibition of these proteins (Activin A and 
Gdf8), we demonstrated that they appear to play key individual roles in the progression 
of the concomitant muscle atrophy observed in NASH patients. Interestingly, superior 
efficacy was gained with the treatment of a pan inhibitor of these proteins (Activin A, B, 
Gdf8 etc.) via a soluble decoy receptor (ActRIIB-Fc), suggesting an additional 
unaccounted for ligand. Activin B, was found to be increased in two separate in vivo 
models of liver fibrosis (two-hit model and BDL), has been implicated in regulating 
muscle mass. Our data suggest a pivotal role for several members of the TGFβ 
superfamily in NASH associated muscle atrophy. Therapies designed to treat liver 
fibrosis and the resultant decrements in muscle mass and force must account for these 
xii 
 
 
agents which will require pan inhibition of TGFβ superfamily ligands that signal through 
the ActRIIB receptor. 
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CHAPTER 1.  INTRODUCTION 
 
 
 
1.1 Objectives 
The purpose of our studies is to determine the role of TGFβ superfamily signaling in 
NASH pathology, with specific focus on liver and muscle cross-organ relationships 
involved in concomitant muscle atrophy observed in patients. While data has been 
generated that demonstrates the importance of TGFβ/Smad signaling in liver disease and 
muscle atrophy separately, limited evidence exists that highlights the commonalities of 
TGFβ signaling in both tissues. Furthermore, the impact of sarcopenia on health and 
prognosis of liver disease (including NASH) patients  is a burgeoning field that carries 
great promise for novel therapeutic options to better treat those stricken with such 
diseases. We postulate that understanding the elements involved in liver disease that 
result in sarcopenia is an opportunity to explore an endocrine relationship that has novel 
implications on diseases with large unmet medical need. 
 
The central hypothesis of this thesis is that TGFβ factors modulate NASH progression 
and directly initiate muscle atrophy programs which are responsible for concomitant 
sarcopenia.  
 
To test this hypothesis, we defined the following objectives: 
1. Evaluate and characterize a 2-hit in vivo model of NASH 
2. Determine whether TGFβ superfamily signaling plays a role in NASH disease 
progression in vivo and whether those effects can be recapitulated in vitro 
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The outcome of this proposal could potentially identify a novel endocrine relationship 
between liver and muscle that contributes to the concomitant muscle atrophy 
accompanied with end-stage liver diseases. Furthermore, inhibition of these hepatic-
based factors defining the molecular underpinnings of the endocrine relationship could 
provide substrate for seminal targets for a disease with large unmet medical need. 
 
1.2 Organization 
In order to better help familiarize the reader to the field of TGFβ signaling in liver and 
muscle biology, this thesis consists of a literature review (Chapter 2), with particular 
emphasis on liver regeneration and muscle atrophy. Also in Chapter 2, there is a literature 
review on NASH and related liver diseases with particular emphasis on the impact those 
disease have on muscle atrophy. Chapter 3 describes the materials and methods used in 
the research. Experimental results collected throughout our research are presented in 
Chapter 4. Discussion of the impacts of our findings, and potential future efforts are 
presented in the discussion section (Chapter 5).  
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 LITERATURE REVIEW CHAPTER 2.
 
 
 
2.1 Etiology of liver disease 
The liver plays a vital role in regulating many of the nutrient constituents found in blood 
such as glucose, protein and fat. In addition, the liver also serves as the master 
“detoxifier” of the body by cleansing the system of many harmful substances as well as 
removing old, worn out red blood cells. As a result of its perpetual exposure to a 
multitude of both natural and synthetic chemicals, the liver is subjected and susceptible to 
constant injury and the need for rapid repair. If left uncorrected, chronic liver injury 
eventually leads to the development of liver fibrosis. Liver fibrosis is a multi-cellular 
process that is highly conserved and specifically well-coordinated. In the early stages of 
liver injury and cell death, liver cells or hepatocytes, are quickly surrounded by 
infiltrating immune cells that can produce cell activating substances. These substances 
are comprised of reactive oxygen species and inflammatory cytokines leading to the 
activation of perivascular hepatic stellate cells (HSCs) (Safadi and Friedman, 2002). 
HSCs work closely with injured and uninjured hepatocytes, hepatic macrophages 
(Kupffer cells) cholangiocytes, endothelial cells and infiltrating immune cells in 
orchestrating the fibrotic response (Seki et al., 2015). Initially, activated HSCs generate 
plenteous amounts of abnormal extracellular matrix components (consisting of collagen, 
other glycoproteins, and glycans), resulting in a temporary scar at the site of injury 
protecting the liver from incurring any additional damage by providing mechanical and 
architectural support (Yin et al., 2013). However, when the liver is under constant injury 
and remodeling, a maladaptation of regeneration occurs leading to decompensated state 
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resulting in excessive agglomeration of ECM negatively affected liver dysfunction, most 
notably liver fibrosis. The key environmental influences that lead to liver fibrosis include 
chronic alcohol abuse, virus C infection and a diet composed of high fat and cholesterol 
can promote liver fibrosis and the eventual development of cirrhosis (Bataller et al., 
2005).  
 
2.2 NASH 
Nonalcoholic fatty liver disease (NAFLD), a precursor to nonalcoholic steatohepatitis 
(NASH), is the most common cause of liver disease in the world, affecting nearly 30% of 
individuals. Due to its strong relationship to obesity and metabolic disorders, NAFLD is 
considered the hepatic manifestation of metabolic syndrome. Concordant with increasing 
global rates of obesity, the prevalence of NAFLD patients have been increasing, and are 
projected to continue rising for the foreseeable future (Dowman, Tomlinson, & 
Newsome, 2011). NAFLD’s pathology is defined by the excessive accumulation of lipids 
(in the form of triglycerides) in the liver in the absence of excessive alcohol intake. In 
some cases, NAFLD may advance into the more aggressive form of liver disease, NASH. 
In addition to the primary steatosis, characteristic pathology of NASH includes the 
essential hallmarks of disease such as hepatocyte injury, inflammation, and fibrosis. 
NASH can progress into liver cirrhosis and hepatocellular carcinoma (HCC), requiring 
liver transplantation (MacHado & Diehl, 2016). By 2020, it is projected that NASH will 
be the leading cause of liver transplants in the United States (Kneeman, Misdraji, & 
Corey, 2012).  
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Disease progression in NASH is not fully understood, but is believed to encapsulate 
multiple stages of injury, or “hits”, that accumulate in the liver. Tilg and Moschen 
proposed the parallel multiple hit hypothesis that outlined a complicated interplay 
between a number of parallel hits (e.g. disrupted lipid metabolism, lipotoxicity, oxidative 
stress, mitochondrial dysfunction, ER stress, gut derived endotoxins, altered cytokines 
and adipokines, and genetic predisposition) (Tilg & Moschen, 2010). Although the 
pathology of NASH is not linear, it can be visualized in a way that outlines the 
progressive severity of the disease (Figure 2.1).  
 
 
Figure 2.1 Disease progression of a healthy liver through NAFLD, NASH, and HCC.  
 
Although significant progress has been made in the diagnosis, there is still debate 
surrounding a more accurate and exact diagnosis for NASH. Standard diagnosis, entails 
the use of liver biopsies to assess the degree and presence of steatosis, lobular 
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inflammation, hepatocellular ballooning, perisinusoidal fibrosis, hepatocellular 
glyocgenated nuclei, lipogranulomas, acidophil bodies, fat cysts, Mallory bodies, iron 
deposition, and megamitochondria. Although it is not considered to be mandatory for a 
NASH diagnosis, fibrosis is considered to be one of the most important pathologies in 
determining severity of the disease and its potential progression (Dowman et al., 2011). 
  
2.3 Liver and muscle 
The liver and the skeletal muscle system have a well-established interdependent 
endocrinological connection in both normal physiological and pathological states. For 
example, in normal physiological states, these two organs equally contribute to the 
maintenance of glucose homeostasis by storage and metabolic mechanisms. Conversely, 
this interdependent relationship has been highlighted in more pathological states and 
continues to be expounded on in both clinical and preclinical settings.  Clinically, patients 
with liver cirrhosis exhibit irregularities in their ability to store glucose as glycogen in 
skeletal muscle (Kruszynska et al., 1988). Furthermore, muscle wasting or sarcopenia is a 
common and frequently disregarded comorbidity that adversely affects quality of life, and 
even recovery from surgery or even infection (Montano-Loza et al., 2014).  
This severe mode of muscle wasting has generally been found to be an effective predictor 
for mortality in a multitude of diseases. Patients with cirrhotic livers and 
contemporaneous muscle atrophy tend to have lower survival rates and more 
complications post-liver transplant. Paradoxically, most complications in liver cirrhosis 
patients resolve following a successful transplant, except for the underlying muscle 
wasting which in some incidents may actually worsen (Dasarathy et al., 2016). In a cross 
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sectional Korean study, subjects with radiological evidence of hepatic steatosis has a 
greater decrement in appendicular muscle mass (determined by bioelectrical impedance) 
as the NAFLD activity score increased (Koo et al., 2016). Moreover, even muscle 
function may also provide clinical utility. There is now evidence that demonstrates the 
value of reversing muscle loss in cirrhotic patients may be beneficial. This was 
underscored in a study where men treated with testosterone who were diagnosed with 
cirrhosis of the liver and low serum testosterone was able to safely promote muscle mass, 
bone mass and hemoglobin, while in parallel reduce fat mass and HbA1c (Sinclair et al., 
2016).  Studies are ongoing to verify the value of increasing muscle mass and the long 
term consequences on survival.  
It is of paramount importance to further the understanding and characterize the systemic 
cues that initiate these sequences of events. It has been proposed that members of the 
TGFβ family play integral roles in moderating the growth and disease states of both liver 
and skeletal muscles while certain members may serve as a nexus between the two organs 
(Tsuchida, 2004). Nonetheless, it is imperative to ascertain which specific TGFβ 
members are involved in the cross-talk between the two organs.   
 
2.4 TGFβ signaling 
The transforming growth factor-β (TGFβ) superfamily is an ever evolving and 
unremittingly expanding group of factors, comprised of 33 genes encoding for 
polypeptides that exist as either homo or heterodimers. The members of the superfamily 
include bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs), 
Activins (ACTs), Inhibins (INHs), and glial-derived neurotrophic factors (GDNFs), as 
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well as some proteins not included in the above families, such as Müllerian inhibiting 
substance (MIS), also known as anti-Müllerian hormone (AMH), left-right determination 
factor (Lefty), and nodal growth differentiation factor (Nodal) (Figure 2.2)  (Poniatowski 
et al., 2015). TGFβ superfamily ligands trigger their downstream effects via interactions 
with the extracellular domains of specific type II receptors (e.g. TGFBR2, ACTRIIA, 
ACTRIIB, BMPR2 etc.) consequently inducing a conformation change. The 
conformational shift enables the recruitment and phosphorylation of their respective type 
I receptor and their intracellular serine residues through its serine/threonine kinase 
domain. There are seven known type I transmembrane receptors identified as Activin 
receptor-like kinases (ALK1-7). Activation of the type I receptor initiates an intracellular 
signaling cascade through the carboxy-terminal phosphorylation of a set of receptor 
regulated transcription factors known as Smads or R-Smads. The activated R-Smads will 
then form an olgiomeric complex with a co-Smad and traverse into the nucleus to where 
it transduces extracellular signaling by modifying specific target gene expression (Lagna 
et al. 1996; Zhang et al. 1996; Kawabata et al. 1998).  
 
Generally in most cell contexts, Activins and TGFβs will induce the phosphorylation of 
R-Smad2 and Smad3, while BMPs will employee the R-Smad1, Smad5, and Smad8 
transcription factors for their transduction. The TGFβ superfamily members and their 
downstream signaling are both highly conserved throughout species and are implicated in 
numerous physiological processes that include cellular proliferation, inflammation, body 
mass control, tissue healing, epithelial–mesenchymal transition (EMT), and extracellular 
matrix (ECM) remodeling (Akhurst & Hata, 2012). The TGFβ family requires a high 
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level of precision in the balance of activity and expression to preserve tissue integrity and 
anomalies in this regulation can contribute to the pathogenesis of the sequelae stated 
above. 
 
 
Figure 2.2 The TGFβ superfamily. 
 
2.5 TGFβ signaling in liver biology 
Liver has a remarkable ability to regenerate following injury and partial hepatectomy (up 
to 70%) (Fausto et al, 2006; Michalopoulos, 2007). Following development, the liver 
maintains a residential progenitor cell population that inhabits areas in the portal triad. 
Upon activation, these unique cells give rise to nascent hepatocytes (Fougere-
Deschatrette et al, 2006; Oertel & Shafritz, 2008, Font-Burgada J et al., 2015) (Figure 
2.3). The liver’s unique ability to preserve its size and mass in spite of constant damage 
and ongoing repair necessitates well-orchestrated processes that are stringently regulated 
and controlled by these cells. Aberrant coordination of these regenerative processes is 
evident in liver fibrosis leading to scarring (cirrhosis) and eventual liver failure. The 
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TGFβ superfamily plays a definable role in maintaining liver homeostasis and has been 
revealed that disruption in its signaling and expression can afflict the liver resulting in 
several diseases such as NASH, hepatocellular carcinoma (HCC) and cirrhosis. Activin 
and Inhibin proteins are members of the TGFβ superfamily, that have been described as 
potent regulators of inflammation and differentiation of many cell types found in the 
liver. More specifically, Activin A has been described as a versatile cytokine and a major 
culprit in promoting hepatic inflammation, fibrosis and remodeling. Higher levels of 
Activin A protein have been observed in fibrotic livers. These findings have also 
translated over to humans where increased serum Activin A levels were found in NASH 
patients when compared to obese or lean controls (Polyzos et al., 2016).  Although the 
mechanisms have not been fully explained, Activin A has been implicated in the 
manifestation of the liver fibrosis through its reported production of collagen and TGFβ1.   
Additionally, in liver precursor and HSCs, Activin A increases the stimulation of a key 
regulator of ECM deposition known as connective tissue growth factor (CTGF) (Ding et 
al., 2016).  
 
 
Figure 2.3 HSC-Hematopoietic stem cells, FLSPC-fetal liver stem/progenitor cells, 
MSC-mesenchymal stem cells, and ES-embryonic stem cells. 
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Activin A also plays a significant role in cellular division and death. Activin A 
simultaneously inhibits proliferation and induces apoptosis of hepatocytes which may 
assist in the cessation or final stages of liver regeneration. Similar to hepatocytes, 
progenitor cell activation and subsequent replication may also be mediated by the 
presence of Activin A.  The anti-mitogenic effect of Activin A has been corroborated, 
both in vitro and in vivo (Hully et al, 1994; Schwall et al, 1993). The in vitro validation 
and mechanism has been delineated in several studies. In one study, a simple experiment 
was conducting measuring the effects of Activin A on epidermal growth factor (EGF)-
induced DNA synthesis in cultured rat hepatocytes. Hepatocyte DNA synthesis was 
blocked by the presence of Activin A overcoming the up regulation and proliferative 
effects of Follistatin generated by EGF (Niimi et al, 2002). Complementary, in the highly 
proliferative hepatoma cell line HepG2 cells, one group demonstrated Activin A via 
Smad2 nuclear translocation induced apoptosis comparatively to that of TGFβ. This 
effect could then be ablated by blocking the downstream propagation of Activin receptor 
IIB activation using a dominant negative approach. (Wei Chen et al., 2000).  
Small hepatocytes are a subpopulation of liver cells that have a high propensity for 
growth and the ability to differentiate into mature hepatocytes supporting growth and 
homeostasis. Inhibition of the Activin natural antagonist Follistatin with an inhibiting 
antibody resulted in suppression of DNA synthesis in small hepatocytes presumably 
through the increasing the bioavailability of Activin A and presumably Activin B (Ooe et 
al, 2012).  
 
12 
 
 
This claim continues to be substantiated in studies monitoring hepatic oval cell 
proliferation. Oval cells may also play a critical function as facultative liver stem cells. 
Exogenous Activin A treatment on an oval cell line (LE6) robustly inhibited proliferation 
in a dose dependent manner by down regulating cyclin E and cyclin D1 while increasing 
cyclin dependent kinases p15
INK4B
 and p21
WAF1
. This effect was then reversed by the co-
incubation of Follistatin protein (Chen et al., 2014).  
 
In vivo animal models that demand high levels hepatocyte proliferation such as partial 
hepatectomy Activin A mRNA levels have been shown to rapidly decrease within 12 
hours following surgery (Gold et al, 2005). Once cellular division has reached the proper 
threshold, it will cease and Activin A levels will rise to assist in the completion of 
regeneration and restore liver micro-architecture by stimulating tubulogenesis of 
sinusoidal endothelial cells and collagen production by hepatic stellate cells (Endo et al, 
2004; Wada et al, 2004). Follistatin has been shown to reverse many of the effects 
presumably elicited by Activin A. In model, a single intraportal administration of 
Follistatin accelerated liver regeneration by amplifying the initial bout of DNA synthesis 
as confirmed by bromodeoxyuridine (BrdU) labeling (Kogure et al, 1995). However, if 
continued treatment of Follistatin persists then, liver architecture may not be restored to 
its fully functional state. 
 
In an animal model that reflects aggressive liver fibrosis, treatment of Follistatin has been 
found to ameliorate the histopathological signature of this disease (Endo et al, 2006; 
Patella et al, 2006). In this model, liver fibrosis was induced with chronic CCl4 
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administration and rats were concurrently administered recombinant Follistatin protein. 
Follistatin treated rats had significantly less alpha-smooth muscle actin staining, TUNEL-
positive cells and hepatic hydroxyproline content indicative of attenuated fibrosis. The 
efficacy produced by Follistatin presumably would be attributed mostly to inhibition of 
Activin A, as blocking its activity with a selective antibody protects the liver from CCl4 
induced injury (Wang et al, 2013). These data also correlate to the human studies 
described earlier with the positive correlation of Activin A expression and severity of 
liver disease.  
 
Along the same vein as liver disease, the natural process of aging presents an additional 
problem, due to the progressive loss in liver plasticity and a attenuated proliferative 
response leading to a deficiency in complete regeneration (Timchenko, 2009). 
Preclinically this regenerative inadequacy has been ascribed to concomitant age 
dependent increases in hepatic Activin A levels, as livers of older rodents (greater than 19 
months) and older individuals (greater than 65 years of age) (Menthena et al, 2011) 
displayed increased transcript and protein expression levels. Rats as early as two months 
old were found to have higher levels of Activin A protein that continued to rise until they 
reached 19 months of age. Analogous to the above-mentioned study, Activin A was also 
discovered to increase a cyclin dependent kinase inhibitor, p15INK4b, which may be 
responsible for driving cells into quiescence and may eventually lead them to senescence. 
Increased sensitivity to Activin signaling in aged rats was also found as denoted by the 
reduction in Ki-67 positive cells. Correspondingly, these findings display a level of 
congruence imparting higher confidence in their ability to translate to human disease.  
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2.6 TGFβ signaling in skeletal muscle biology 
TGFβ family members have been implicated in both homeostasis and disease, but only 
limited members have been studied in skeletal muscle. In this outline we will review the 
current findings of the two key members (Activin A and Gdf8) of the TGFβ family along 
with a natural antagonist (Follistatin) and their role in muscle.  
 
Myostatin, or growth and differentiation factor-8 (Gdf8), is a well know member of the 
TGFβ superfamily. While a number of TGFβ members have been shown to influence 
muscle growth, Gdf8 is considered one of the more dominant negative regulators of 
skeletal muscle mass that is extensively conserved throughout the mammalian species. It 
is operative during development and adulthood and these roles have been heavily 
examined since its advent. Gdf8 precursor protein is secreted in an unprocessed pro-form. 
The mature form of Gdf8 is derived from the proteolytic processing of its precursor. This 
process of activating of myostatin is facilitated through the cleavage of the propeptide by 
the bone morphogenetic protein (BMP)-1/tolloid family of metalloproteinases (Elkina, 
von Haehling, Anker, & Springer, 2011,and Szláma, Trexler, & Patthy, 2013).  
Activated Gdf8 will then bind to its primary cognate receptor, Activin IIB receptor 
(ActRIIB), or in some cases even Activin IIA receptor (ActRIIA) (Gilson et al, 2009; 
Huet et al, 2001; Sako et al., 2010). Once bound, Gdf8 will elicit a cascade of events that 
lead to the translocation of regulatory Smads 2/3 to the nucleus and alteration of gene 
expression (Han et al, 2007; Welle, 2009) (Figure 2.2). The Gdf8 mediated gene response 
is the primary suppressor on the activation of skeletal muscle satellite cells and disrupting 
the balance of protein synthesis/degradation. Gdf8 has been shown to be an anti-
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proliferative agent in satellite cell expansion by the strict modulation of Pax7 and Myod1 
gene expression in conjunction with cell cycle control factors (McCroskery et al, 2003; 
McFarlane et al, 2008).  
 
In terms of protein metabolism and muscle growth, Gdf8 is culpable for the down-
regulation of the Akt/mTOR signaling pathway, as evidenced by the decreased 
phosphorylation of AKT. The Akt/mTOR pathway is the main driver in promoting 
skeletal muscle anabolism and it down regulation is responsible for skeletal muscle 
atrophy (Rodriquez et al., 2014).  In summary, dysregulation of Gdf8 can affect both 
skeletal muscle plasticity and hypertrophy.  
 
It has been well documented that neutralization, reduction or deletion of gene expression 
will have profound effects on stimulating muscle growth. Several laboratories and 
pharmaceutical companies have developed a multitude of methods that impede Gdf8 
signaling such as neutralizing antibodies, natural protein inhibitors, siRNA and even gene 
therapies.  Innumerable preclinical studies have provided evidence that inhibition of Gdf8 
can improve both muscle mass and strength in multiple disease states. For instance, 
tumor bearing cachectic (C26 colon adenocarcinoma and PC3 prostate carcinoma) mice 
treated with a Gdf8 neutralizing antibody was able to significantly preserve muscle mass 
and strength (Smith et al., 2015). Additionally, in aged mice (22 months), 4 weeks of 
Gdf8 antibody treatment demonstrated a 7% increase in lean body mass and a 20% 
increase in grip strength improving both quality and quantity of muscle. Unexpectedly, 
these studies revealed that Gdf8 inhibition also provided a modest improvement in insulin 
16 
 
 
sensitivity (Camporez et al., 2016). This augmentation of skeletal muscle metabolism and 
insulin sensitization was also substantiated in another study where reductions in Gdf8 
mRNA increased glucose uptake in type 1 diabetic (Akita) mice by upregulating glucose 
transporters Glut1 and Glut4 (Coleman et al., 2016). These therapeutic modalities have 
clearly demonstrated the potential clinical utility for a myriad of muscle and metabolic 
disorders (Bogdanovich et al, 2005; Murphy et al, 2011; Tsuchida 2008; Wagner et al, 
2002).   
 
 
Figure 2.4 Cross-talk between myostatin/Activin A and BMP signaling in skeletal 
muscle. Sartori, Trends in Endocrinology and Metabolism September 2014. 
 
More recently, studies have uncovered other TGFβ members as intermediaries of skeletal 
muscle physiology. One group found that a Follistatin transgenic mouse produced a 
robust muscle hypertrophy phenotype greater than what had been observed by myostatin 
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deletion (Lee, 2007). These findings suggest additional TGFβ members can modulate 
muscle growth and development.  
 
Empirical confirmation of these data was seen in an experiment by Lee et al., where Gdf8 
null mice were crossed with mice carrying a Follistatin transgene (Lee, 2007). These 
mice exhibited extreme muscle growth when compared to the Gdf8 null mice, 
reaffirming the existence of other regulators of muscle mass. An experiment utilizing 
another broad inhibitor of the TGFβ superfamily, ActRIIB-Fc (engineered molecule that 
fuses the ECD of Activin receptor IIB to an Fc domain of IgG1), also produced similar 
results. Treatment with the ActRIIB-Fc decoy receptor in a Gdf8 null background 
produced additional gains in muscle mass reiterating that the presence of other regulators 
specifically signal through the ActRIIB receptor (Lee et al, 2005). Follistatin is a natural 
antagonist to several members of the TGFβ pathway including both Gdf8 and Activins A 
and B. Akin to FST; ActRIIB-Fc also binds many of the same members providing a 
focused substrate in identifying the additional muscle regulators modifying skeletal 
muscle. 
 
Predicated on these data, Activin A appears to be the most likely suspect affiliated with 
muscle. Activin A belongs to the Activin subgroup of the TGFβ family, which is 
comprised of many members that are formed through the dimerization of the following 
four subunits: βA, βB, βC, and βE (Carney et al, 2011; Mellor et al, 2003; Mellor et al, 
2000). The Activin A protein complex is comprised of a disulphide-linked homodimer 
containing two of the aforementioned βA-subunits. Similar to Gdf8, once Activin A is 
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processed and secreted, it can elicit a Smad based gene response by binding to its 
respective receptors, ActRIIA and IIB.  
 
Activin A has been linked to etiologies of multiple diseases ranging from cancer 
metastasis to osteoporosis (Fajardo et al, 2010; Leto, 2010; Leto et al, 2006; Lotinun et 
al, 2010; Terpos et al, 2012). Activin A shares some functional overlap with Gdf8 in 
terms of skeletal muscle as illustrated by He et al. Studies from this group demonstrated 
that muscle precursor cells treated with Activin A blocked the expression of the two key 
myogenic transcription factors, Pax7 and Myod1, resulting in a loss of activation and 
differentiation much akin to Gdf8 (He et al, 2005; Wagner, 1993).   Effects of Activin A 
on satellite precursor cells were also supported by data generated by Yaden et al., where 
it was ascertained that the inhibition of Activin A lead to an increase of Pax7 positive 
cells in a model of muscle injury and regeneration.  In the article, local exposure of 
normal muscle to Activin A was shown to reduce myofiber diameter and activate 
myocellular degeneration through the concordant activation of inflammation and the 
induction of muscle atrophy via E3 ligases (Yaden et al., 2014). Another group 
expounded on this finding and showed that Activin A stimulated muscle catabolism both 
in C2C12 myotubes and mice and was solely dependent on p38β MAPK signaling (Ding 
et al., 2016).  Lastly, elevated systemic levels of Activin A have been shown to engender 
a phenotype reminiscent of severe cachexia by engaging in the myostatin pathway (Chen 
et al., 2014). 
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To conclude, studies need to investigate the relevance of Activin A and Gdf8 along with 
additional TGFβ members and define their overall contribution to liver disease and the 
concurrent muscle atrophy.  
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 MATERIALS AND METHODS CHAPTER 3.
 
 
 
3.1 Animal care and use 
All mouse experiments were performed with the approval of Eli Lilly and Company’s 
Institutional Animal Care and Use Committee and are in accordance with the National 
Institute of Health Guide for the Care and Use of Laboratory Animals. 
For diet-induced obesity (DIO) studies, male C57BL/6 male mice were used (Jackson 
Laboratories, Bar Harbor, ME). DIO animals were placed on a high-fat diet (Research 
Diets, New Brunswick, NJ) with 60% kcal from fat at 6 weeks of age, and purchased 14 
weeks later. Age-matched control animals were fed standard chow (TD 5001 with 0.95% 
calcium and 0.67% phosphorus, Teklad, Madison, WI) for the same period of time. 
Animals were acclimated for 2 weeks in a temperature controlled room ((22±2°C), and a 
12:12 hour light-dark cycle (lights on at 6:00 am) with ad lib access to food and water 
prior to beginning of study. Mice were then randomized into treatment and control groups 
according to body weight prior to the beginning of the study. 
 
3.2 Carbon tetrachloride (CCl4) induced liver injury 
For longterm studies hepatic fibrosis was induced by intraperitoneal (IP) injections of 1:5 
dilution of CCl4 (Sigma Aldrich) in corn oil (1 ml/kg) twice weekly for 1 or 4 weeks. The 
mice in normal control groups received only corn oil injections for the duration of the 
study in the same dosing regimen of CCl4. For acute studies, animals received a single 
dose of CCl4. Twenty four hours after the final administration of CCl4, animals were 
anesthetized with isoflurane, and blood was collected via cardiac puncture before 
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secondary euthanasia by means of cervical dislocation. Following secondary euthanasia, 
liver and muscles were excised, weighed, and snap frozen in liquid nitrogen. Tissue and 
serum samples were kept frozen at -80 °C until analyzed.  
 
3.3 Combination of CCl4 injury and DIO model 
Hepatic injury was induced as described above. Animals were provided ad lib access to 
high fat chow for at least 22 weeks prior to start of study and high fat feeding was 
maintained throughout the experiment. 
 
3.4 Bile duct ligation 
Bile duct ligation studies were performed as previously described (Tag et al., 2015) in 
male Sprague Dawley rats. Animals were sacrificed as previously described 3 hours, 6 
hours, 12 hours, 24 hours, 4 days, 6 days, 11 days, and 15 days after surgery. 
 
3.5 Inhibition of TGFβ family members 
TGFβ family members were inhibited in vivo using antibody therapies dosed at 10 mg/kg 
24 hours prior to CCl4 administration. Anti-Gdf8 and anti-Activin A antibodies were 
obtained from Eli Lilly and Company (Indianapolis, IN), and Actr2b-Fc antibody was 
obtained from Acceleron Pharma (Cambridge, MA).  
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3.6 Body composition (quantitative NMR) 
Lean body mass, fat mass, and free water content were measured using nuclear magnetic 
resonance once weekly throughout the studies (NMR; Echo Medical systems, Houston, 
TX).  
 
3.7 Biochemical assays 
Blood was collected via cardiac puncture 24 hours after the final CCl4 administration, and 
serum was separated using Multivette 600 Z-Gel serum separating tubes (Sarstedt, 
Nümbrecht, Germany). Serum aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), glucose, and total bilirubin (T-Bil) were assayed with a Hitachi 
Modular Analyzer (Roche Diagnostics, Indianapolis, IN). 
Serum FGF21 and CD14 protein content was assayed via ELISA kits provided by R&D 
systems (MF2100 and MC140, respectively). Hepatic FGF21 was quantified using the 
same ELISA kit. Serum Activin B protein content was analyzed via ELISA kit (Ansh 
Labs, Webster, TX).  
 
Serum Activin A protein was assayed after samples underwent treatment with 10mM 
DTT in PBS for 1 hour at room temperature prior to plating. The antibody was coated 
and was reconstituted in PBS to a final concentration of 100 µg/mL (R&D Systems 
#AF338, Minneapolis, MN). One hundred microliters per well of antibody were diluted 
to 1 µg/mL in coating buffer (Hyclone SH30256.01, Waltham, MA), incubated 1 hour at 
37°C, blocked for 1 hour, then samples were incubated at room temperature for 1 hour. 
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Poly streptavidin-HRP and TMB block steps were performed and plates were read at 
450-630 nM. The ELISA was validated using purified Activin A protein. 
 
3.8 Histology 
Liver and muscle tissues were processed and embedded in paraffin using standard 
methods. Histology was evaluated using hematoxylin and eosin (H&E) staining and 
Mason’s trichrome staining at 5µm. Liver sections were stained using a trichrome 
staining kit purchased from Abcam (Cambridge, MA). Hydrated slides to water and place 
in Bouin’s fixative for 1 hour at 56°C in a preheated dish or jar.  Samples were then 
placed Bouin’s fixative overnight at room temperature. Sections were rinsed in distilled 
water and placed in Weigert’s iron hematoxylin solution for 10 minutes.  Samples were 
washed in running tap water for 10 minutes then placed in Biebrich scarlet-acid fuchin 
solution for 17 minutes. Samples were then rinsed and placed in phosphomolybdic-
phosphotungstic acid solution for 10-15 minutes. Sections were transferred directly to the 
aniline blue solution for 20 minutes.  Sections rinsed in distilled water and dehydrate, 
clear in xylene, and then cover-slipped, using a synthetic mounting medium. 
For each muscle, the distribution of the fiber diameter was calculated by analyzing 100 to 
150 myofibers. Images were acquired using digital slide scanning (ScanScope XT, 
Aperio, Vista, CA). 
 
3.9 Quantitative real-time PCR 
mRNA analysis of liver and muscle was performed via qRT-PCR on RNA extracted from 
tissues using TRIzol reagent and the PerfectPure RNA 96 CellVac Kit (5 PRIME, 
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Germany). RNA purity was calculated using absorbance at 260/280 nm quantified via 
Nanodrop (ThermoFisher Scientific, Wilmington, DE). 2 µg of extracted RNA was 
reverse transcribed using a MultiScribe MuLV high capacity cDNA reverse transcription 
kit (ThermoFisher Scientific, Wilmington, DE) in a 50µL reaction. The resulting cDNA 
was combined with TaqMan Fast Universal Master Mix (ThermoFisher Scientific, 
Wilmington DE) and specific primer probes (see primerprobe ID on table below) for 
qPCR analysis on the Applied Biosystems 7900HT Fast System (ThermoFisher 
Scientific, Wilmington DE) for 40 cycles in a 10µL reaction. All CT values were 
normalized to GAPDH gene for normalization.  
 
Table 3.1 Taqman primer probe ID numbers for genes used in mRNA expression 
analysis. 
Gene  Probe ID 
Gapdh Mm99999915_g1 
 Inhba Mm00434339_m1 
 Inhbb Mm03023992_m1 
 Gdf8 Mm01254559_m1 
 Gdf15 Mm00442228_m1 
 Trim63 Mm01185221_m1 
 Fbxo32 Mm00499523_m1 
  
3.10 In vitro experiments 
In vitro experiments were performed using primary hepatocytes isolated as previously 
described (Berry, M. N. and Friend, D. S. 1969) and C2C12 myoblasts were obtained 
from ATCC (Manassas, VA). Myoblasts were differentiated in growth media 
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supplemented with 2% horse serum for 5 days with daily media change. Hepatoxins were 
administered directly onto hepatocyte media for 24 hours prior to media collection. 
Unless noted otherwise, CCl4 was administered at 0.5%/volume. Collected hepatocyte 
media was diluted 1:10 in myoblast differentiation media before addition to C2C12 cells. 
After 5 days, muscle cells were imaged and diameter quantified using Aperio 
ImageScope software. Cell media aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), glucose, and total bilirubin (T-Bil) were assayed with a Hitachi 
Modular Analyzer (Roche Diagnostics, Indianapolis, IN).  Hepatocyte media FGF21 was 
analyzed by ELISA kit listed above.  
 
3.11 Data analysis 
All data are expressed as the mean ±SEM. Statistical analysis was conducted using 
GraphPad Prism version 7. Statistical significance (p-value ≤0.05) was analyzed by one-
way ANOVA. 
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  RESULTS CHAPTER 4.
 
 
 
4.1 Characterization of two-hit NASH model 
We evaluated an in vivo model of non-alcoholic steatohepatitis (NASH) to better 
understand the mechanisms of disease progression both in the liver and the concomitant 
muscle atrophy (Kubota et al., 2013). Animals were separated into 8 different groups 
based on diet, duration of time on study, and CCl4 administration (Table 4.1). 
 
Table 4.1 Groups in two-hit in vivo NASH study. 
Group Number Obesity State Hepatotoxin Time on Study 
1 Lean Corn Oil 1 Week 
2 Lean CCl4 1 Week 
3 DIO Corn Oil 1 Week 
4 DIO CCl4 1 Week 
5 Lean Corn Oil 4 Weeks 
6 Lean CCl4 4 Weeks 
7 DIO Corn Oil 4 Weeks 
8 DIO CCl4 4 Weeks 
 
Due to the hepatotoxic and pro-fibrotic effects of CCl4 (Weber, Boll, & Stampfl, 2003), 
we anticipated that characteristic markers of liver injury would be increased following 
administration. To investigate these effects, lean animals that were on a standard chow 
diet (SD) or diet induced obese (DIO) animals fed a high fat diet were injected with CCl4 
intraperitoneally twice weekly (q.a.d.) for one week while another cohort remained on the 
study for 4 weeks. Twenty four hours after the last CCl4 injection, muscle, liver, and 
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blood was collected and the serum was analyzed biochemically for markers of hepatic 
injury. A shorter timecourse was chosen to assess known liver injury responses to CCl4 
that peak roughly 72 hours after injury. The 4 week timepoint replicates the published 
study design, and theoretically provides more time for disease pathology to manifest. At 
both timepoints, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
were dramatically increased in both groups injected with CCl4 (Figure 4.1). Despite their 
significant obesity, the DIO animals, without CCl4 injury, did not have elevated serum 
ALT or AST levels compared to their lean controls. After 4 weeks of injury, animals 
started to show signs of liver failure (as determined by diminished hepatic 
gluconeogenesis, bilirubin processing, and histopathological features) which likely 
caused ALT/AST increases to be less responsive to CCl4. Despite this effect, AST levels 
in the DIO+CCl4 combination group exhibited greater AST levels than lean+CCl4 
controls suggesting enhanced disease progression in the DIO+CCl4 animals.  
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Figure 4.1 Biochemical assessment of the two hit model. DIO male C57BL/6 mice 
were chronically administered CCl4 for either 1 or 4 weeks. Male C57BL/6 serum was 
collected via cardiac puncture 24 hours after the final CCl4 injection. After 2 injections, 
ALT (A) and AST (C) were increased in circulation independent of diet. After 4 weeks of 
biweekly CCl4 injections, ALT (B) and AST (D) levels were increased compared to corn 
oil controls, but the magnitude of the increase was blunted. At this timepoint, the 
combination of DIO+CCl4 exhibited significantly increased AST levels compared to 
those of lean CCL4 controls. Data are expressed as means ± S.E.M. of 5 mice per group. 
Significance is indicated *P ≤ 0.05 (Dunnett’s one-way ANOVA). 
  
While there is some evidence that increased hepatocellular triglycerides may protect 
against liver injury acutely (Cusi, 2012), the histology suggests diminished liver 
triglycerides at the later timepoint, and the indications of liver failure (Figure 4.2) are a 
result of a pronounced liver pathology after 4 weeks of insult. Increased total bilirubin 
and reduced hepatic gluconeogenesis after 4 weeks was only observed in the DIO+CCl4 
cohort. This reduced hepatic function along with increased ALT/AST levels is suggestive 
of a natural proclivity to greater injury due to residual adiposity in these animals. 
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Figure 4.2 Functional assessment of the two hit NASH model. DIO male C57BL/6 
mice were chronically administered CCl4 for either 1 or 4 weeks. At the end of the 
studies, serum levels of bilirubin (A & B) and glucose (C & D) were measured as 
indicators of liver injury and function. Data are expressed as means ± S.E.M. of 5 mice 
per group. Significance is indicated *P ≤ 0.05 compared to corn oil control P ≤ 0.05 
(Dunnett’s one-way ANOVA).  
 
The two-hit model of NASH was chosen in order to emulate both the peripheral 
characteristics of metabolic disorder along with the hepatic damage associated with 
fibrosis as a result of chronic injury (Buzzetti, Pinzani, & Tsochatzis, 2016).  
In order to assess the presence of standard pathological features of NASH development in 
the liver, hemotoxylin and eosin (H&E) staining was performed. Lean mice fed standard 
chow diet (SD) with no injury lacked any abnormal features, while DIO mice without 
injury exhibited abundant steatosis (the hepatocellular storage of lipid droplets), 
especially near zone 3 (Figure 4.3). NAFLD and NASH involve a multitude of 
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pathologies associated with obesity and metabolic syndrome including an increase in 
circulating pro-inflammatory milieu, insulin resistance, and increased free fatty acids 
(FFA) which result in altered glucose and lipid metabolism that drive lipid accumulation 
in the hepatocytes (Rinella, 2015). Independent of CCl4 administration, DIO animals 
showed significant steatosis, while SD animals showed little to no steatosis at either time 
point (Figure 4.3). Interestingly, steatosis was reduced after 8 injections of CCl4 along 
with high fat feeding. This finding was consistent with previous studies (Kubota et al., 
2013). Such a reduction in steatosis can most likely be attributed to the overall body 
weight loss related to malnutrition exhibited by these animals reminiscent of high risk 
patients during end stage liver disease (Bambha, Dodge, Gralla, Sprague, & Biggins, 
2015). Additionally, as end stage liver disease progresses, there is a loss of hepatic 
vascular bed function due to an increase in fibrotic tissue (Iwakiri, Shah, & Rockey, 
2014). This phenomenon limits blood flow to the liver which inhibits lipid build up, and 
could likely attribute to the loss of steatosis. Furthermore, reduced hepatic vascular 
function directly inhibits hepatic glycogen metabolism which contributes to the observed 
hypoglycemia. 
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Figure 4.3. Histological evaluation of the DIO+CCL4 NASH model. DIO male 
C57BL/6 male mice were administered CCl4 twice weekly for a period of either 1 or 4 
weeks. H&E staining of two-hit model recapitulates disease pathology in liver. 
Representative H&E (10X) cross-sectional images captured at (A) week 1 and (B) week 
4. 
 
Hepatic secretion of fibroblast growth factor 21 (FGF21) is known to increase in obese 
patients and those with NALFD in response to lipotoxicity and ER stress (Dushay et al., 
2010). We quantified FGF21 via ELISA from serum and isolated liver protein. After 
week 1, both circulating and hepatic FGF21 was higher in DIO animals and elevated in 
animals that had been injured with CCL4 with no increase between CCl4 injury alone 
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compared to DIO+CCl4 animals. (Figure 4.4 A & C). After 4 weeks, both serum and liver 
FGF21 levels in DIO animals remained elevated over lean controls. Interestingly, the 
increase of FGF21 in animals following CCl4 injections seen at week 1 was blunted in the 
liver, and eliminated altogether in circulation of lean animals (Figure 4.4 A & B; C & D). 
Similarly, there is a significant increase of FGF21 in DIO+CCl4 compared to lean+CCl4 
injury alone (Figure 4.4 B & D). This suggests increased pathological progression of liver 
disease in the two-hit model over time, and highlights the increased impact of residential 
steatosis when combined with hepatic injury. 
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Figure 4.4 The two hit NASH model increases local and systemic levels of Fgf21. 
Serum and liver Fgf21 protein was measured after 1 and 4 weeks of CCl4 administration 
in DIO mice. Protein expression levels of Fgf21 in liver lysates (A & B) and in serum (C 
& D) were increased with CCl4 administration at both time points. After 4 weeks, 
DIO+CCl4 animals showed increased hepatic and circulating FGF21 compared to lean 
CCl4 control animals. Data are expressed as means ± S.E.M. (n=5 mice/group). 
Significance is indicated *P ≤ 0.05, CCl4-treated group versus corn oil-treated group, # P 
≤ 0.05 DIO group versus lean control group, and † P ≤ 0.05 lean CCl4-treated group 
versus DIO CCl4treated group for the ELISAs and gene expression experiments 
(Dunnett’s one-way ANOVA). 
 
At both the 1) early and 2) long term time points, the two-hit combination of HFD and 
CCl4 displayed ballooning hepatocytes (Figure 4.3), which are a pathological 
characteristic of hepatocellular death that is visualized as markedly swollen hepatocytes 
which display a pronounced cytoplasm along with nuclear hepatocellular hypertrophy. 
Hepatocyte ballooning is a feature of cellular apoptosis in which ATP loss results in 
intracellular calcium level increases that disrupt plasma membrane function and results in 
hepatocellular swelling (Crawford, 2012). This pathology was more pronounced after 4 
weeks of CCl4 injury. Lobular inflammation in the form of increased nuclear eosin 
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staining near zones 2 & 3 was exhibited in the injured livers. Increased liver lobular 
inflammation is a result of the inflammatory response to cellular damage, tissue necrosis, 
and free radical presence caused by CCl4 (Basu, 2003). Since a significant portion of the 
immune response is recruited to the liver from elsewhere, histological assessment shows 
the predominant inflammatory response near portal veins located in zone 3 (Figure 4.3). 
A consequence of increased hepatic inflammation in NASH is a rise in soluble CD14 
protein (Ogawa et al., 2013). CD14 was quantified by ELISA and found to be increased 
in animals that had been injured with CCL4, and significantly elevated in DIO+CCl4 
animals at both timepoints (Figure 4.5). 
 
A related pathological feature seen in the CCl4 challenged livers are Mallory bodies, 
which are present at week 1 and become more prominent after 4 weeks of CCl4 
administration (Figure 4.3) and tend to develop concurrent with the progression of 
fibrosis (Jeong et al., 2005). Mallory-Denk (MDB) bodies are eosinophils inclusions near 
nuclei of ballooning hepatocytes. The inclusions are composed of misfolded intermediate 
keratin filaments, ubiquitin, heat shock proteins, and p62. While the presence of MBD 
are not required for a NASH diagnosis, they are correlated with incidence of cirrhosis, 
and therefore strengthen the diagnosis (Brunt & Tiniakos, 2010). 
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Figure 4.5 Soluble CD14 levels in circulation in NASH model. Serum levels of CD14 
protein levels were measured after 1(A) and 4 (B) weeks of CCl4 administration in DIO 
mice. CD14 was increased by CCl4 treatment at 1 week independent of diet, but 
significantly higher in DIO+CCl4 after 4 weeks. Data are expressed as means ± S.E.M. 
(n=5 mice/group). Significance is indicated *P ≤ 0.05, CCl4-treated group versus corn 
oil-treated group, # P ≤ 0.05 DIO group versus lean control group, and † P ≤ 0.05 lean 
CCl4-treated group versus DIO CCl4treated group for the ELISAs and gene expression 
experiments (Dunnett’s one-way ANOVA). 
 
In order to determine collagen deposition and fibrosis, mason’s trichrome staining was 
performed. After one week, minor perisinusoidal fibrosis was present near zone 3, 
centralized near areas with pronounced inflammation, in livers that were injured with 
CCl4. After 4 weeks of injury, the fibrosis was more pronounced, but was not 
significantly impacted by the presence of steatosis in animals combined on a HFD 
(Figure 4.6).  
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Figure 4.6 Progression of hepatic fibrosis in the two hit model of NASH. Lean and 
DIO male C57BL/6 mice were chronically administered CCl4 for either 1 (A) or 4 (B) 
weeks. Representative cross-sectional images of trichrome stained liver sections (10X) of 
week 1 and week 4 displayed. 
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Transforming growth factor-beta (TGFβ) superfamily members and their known 
downstream SMAD effectors are well understood to play a role in the development of 
hepatic fibrosis (Xu, Liu, Zhou, & Zhang, 2016). In order to understand the response and 
possible role of TGFβ superfamily members in the pathology of our two-hit NASH 
model, we measured TGFβ, growth differentation factor 8 (Gdf8), growth differentiation 
factor 15 (gdf15), inhibin-βa (inhba; subunit of Activin a), and inhibin-βb (inhbb; subunit 
of Activin b) RNA expression via real-time quantitative PCR (RT-qPCR) in the liver at 
both timepoints. When normalized to a housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (gapdh), we observed a significant CCl4 induced increase in INHBA and 
INHBB gene expression after 1 week independent of diet. Gdf15 was increased with 
CCl4 treatment in lean mice, but not in the DIO group. This was likely a result of the 
basal increase in gdf15 expression caused by obesity (Figure 4.7A). At week 4, the only 
increased expression of Activins were in DIO+CCl4 groups. Lean CCl4 animals increased 
expression of Activin A and B had reduced to those of the control groups. Notably, DIO 
animals with no liver injury displayed a decrease in Activin A expression at this 
timepoint. Also at week 4, elevated gdf15 expression was entirely dependent on the CCl4 
injury. Curiously, Gdf8 (also known as myostatin) showed increased mRNA expression 
at this timepoint as well (Figure 4.7 B). This data shows the active response and possible 
regulatory roles TGFβ superfamly members are likely playing in our two-hit in vivo 
NASH model. 
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Figure 4.7. Gene expression analysis of hepatic TGFβ superfamily members.   Lean 
and DIO male C57BL/6 mice were chronically administered CCl4 for either 1 (A) or 4 
(B) weeks. Gene expression analysis was performed by qRT-PCR on liver at 1 and 4 
week post CCl4 injury. Data are expressed as means ± S.E.M. (n=5 mice/group). 
Significance is indicated *P ≤ 0.05, CCl4 treated group versus corn oil control group; † P 
≤ 0.05, DIO group versus lean control group (Dunnett’s one-way ANOVA). 
 
BQL 
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An emerging area of interest in NASH pathology that is not well understood is the 
concomitant muscle atrophy observed in patients (Lee et al., 2016). In order to 
understand the phenomenon and possible mechanisms that drive it, we measured various 
markers of muscle atrophy in our two-hit model. First, we monitored weekly body 
composition by means of quantitative nuclear magnetic resonance (QNMR), and 
observed a flattening in body weight gain in the DIO+CCl4 group, with no difference 
observed in lean animals regardless of liver injury (Figure 4.8 A). Fat-free mass (assumed 
to be lean mass) showed the same trend toward muscle loss in DIO+CCl4 animals (Figure 
4.8 B) that was confirmed by weighing gastrocnemius bundles at the time of sacrifice 
(Figure 4.8 C). Finally, myofiber cross-sectional area was measured in H&E stained 
soleus muscles that demonstrated a 41% myofiber area reduction in DIO+CCl4 animals 
compared to the DIO control (Figure 4.8 D & E). These data clearly show a significant 
ability of our two-hit in vivo NASH model to emulate the concomitant muscle atrophy 
observed in NASH patients. 
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Figure 4.8 The two hit model of NASH negatively affects muscle mass.  Both DIO 
and lean male C57BL/6 mice were chronically administered CCl4 for either 1 or 4 weeks. 
(A) Body weight changes over time course in the two-hit NASH model. (B) QNMR body 
composition measurements of lean mass. (C) Gastrocnemius muscle mass measurements 
on both 1 and 4 weeks. (D)  Representative H&E cross-sectional images of myofibers in 
the gastrocnemius muscle were analyzed. (E) Fiber diameter of gastrocnemius muscles 
(white-corn oil control, black-CCl4). All quantifications of myofibers (~200 counted per 
group) were determined using ImageScope software (Aperio). Data are expressed as 
means ± S.E.M. (n=5 mice/group). Significance is indicated *P ≤ 0.05, CCl4 treated 
group versus corn oil control group; † P ≤ 0.05, DIO group versus lean control group 
(Dunnett’s one-way ANOVA). 
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In order to understand the mechanism of atrophy in the muscles, we analyzed mRNA 
expression via RT-qPCR of Gdf8, gdf15, and ubuitin ligases tripartite motif containing 
63 (trim63) and F-box protein 32 (fbxo32) in gastrocnemius bundles of the animals at 
week 1. We observed no increases in ubuitin ligase expression or Gdf8 in DIO animals 
absent injury, or in lean animals who were injured with CCl4. Gdf15 was the only injury 
marker that showed increased expression in DIO muscle without CCl4 induced injury. 
Most notably, all 4 genes associated with muscle atrophy were significantly increased in 
muscles from the DIO+CCl4 group (Figure 4.9). This data clearly demonstrates the 
requirement of a two-hit approach to replicate the concomitant muscle atrophy observed 
in NASH patients.  
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Figure 4.9 Muscle atrophy genes increased in a two-hit model of NASH. Gene 
exprssion analysis via qRT-PCR was performed on muscles from 1 week post CCl4 
injury and CCl4 injury plus high fat diet (HFD). Data are expressed as means ± S.E.M. 
(n=5 mice/group). Significance is indicated *P ≤ 0.05, CCl4 (+/- HFD) treated group 
versus corn oil control group (Dunnett’s one-way ANOVA). 
 
4.2 In vitro replication of NASH model 
In order to explore the mechanisms involved in a potential liver-muscle cross tissue 
endocrine relationship, we isolated liver and muscle cell types to replicate the two-hit in 
vivo NASH model in an in vitro system. Our goal was to replicate the hepatic challenges 
observed in the two-hit NASH model, and recreate an in vitro environment that induces 
similar muscle atrophy. Primary hepatocytes were isolated from mice, and plated 
overnight. The next day, the cells were challenged with a variety of chemicals in order to 
replicate individual aspects of NASH pathology: CCl4 to generate oxidative stress as well 
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as replicate the in vivo model, lipopolysaccharide to cause an inflammatory response, 
hyodrogen peroxide to generate reactive oxygen species (ROS), and thapsigargin to 
induce ER stress. After 1 day of exposure to various chemical challenges, hepatocyte 
media was collected. The media of insulted hepatocytes was diluted (1:10) and placed on 
mouse myoblasts cells for 5 days, which were allowed to differentiate into myotubes. 
Effects of muscle atrophy and reduced myoblast differentiation were monitored at the 
conclusion of the 5 days via image analysis of myotube diameter.  
 
Oxidative stress by means of CCl4 
Oxidative stress is prominent player as a second hit in the development and progression 
of NAFLD into NASH (Basaranoglu, Basaranoglu, & Sentürk, 2013). The primary 
hepatotoxic mechanism of CCl4 is the development of oxidative stress via the generation 
of trichloromethylperoxy free radicals (Weber et al., 2003). We induced oxidative stress 
in primary hepatocytes by adding CCl4 to the media, and we saw a dose dependent 
increase in ALT and AST levels 24 hours later (Figure 4.10). 
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Figure 4.10 CCl4 induces hepatocellular injury in vitro.  Primary mouse hepatocytes 
were treated with titrated doses of CCl4 for 24 hours. ALT (A) and AST (B) were then 
measured in the media. Data are expressed as means ± S.E.M. (n=3 wells/group). 
Significance is indicated *P ≤ 0.05, CCl4 treated group versus vehicle control group 
(Dunnett’s one-way ANOVA).  
 
ROS generation via H2O2 challenge  
Oxidative stress is believed to be another major contributor to the NASH sequelae. 
Oxidative stress is the buildup of reactive oxygen species (ROS) (H. Fujii & Kawada, 
2012) that play proinflammatory and profibrogenic roles (Chalasani, Deeg, & Crabb, 
2004). In order to accurately reproduce in vitro oxidative stress, hepatocytes were treated 
with H2O2.  Twenty four hours after insult, ALT and AST were dose dependently 
increased in the media confirming hepatocellular stress and damage (Figure 4.11). 
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Figure 4.11 H2O2 induces hepatocellular injury in vitro. Primary mouse hepatocytes 
were treated with titrated doses of H2O2 for 24 hours. ALT (A) and AST (B) were then 
measured in the media. Data are expressed as means ± S.E.M. (n=3 wells/group). 
Significance is indicated *P ≤ 0.05, H2O2 treated group versus corn oil control group 
(Dunnett’s one-way ANOVA). 
 
Thapsigargin induced ER Stress 
ER stress is a contributor to the development of NASH (Bozaykut, Sahin, Karademir, & 
Ozer, 2016), therefore we exposed primary hepatocytes to thapsigargin (Tg) for 24 hours 
(Fang et al., 2013). Thapsigargin is a selective inhibitor of the ubiquitous sarco-
endoplasmic reticulum Ca
2+
-ATPases (SERCAs). Inhibition of SERCAs blocks pumping 
of calcium from the cytosol into the ER lumen and results in a depletion of ER luminal 
calcium stores. This loss of Ca
2+ 
is the primary mechanism behind the ER stress 
observed, and can eventually lead to induction of apoptosis (Canová, Kmoní˘ Cková, 
Martínek, Zídek, & Farghali, 2007). ER stress has also been linked to FGF21 secretion 
(Schaap, Kremer, Lamers, Jansen, & Gaemers, 2013), so we measured FGF21 protein in 
the hepatocyte media and saw a dose responsive increase indicative of ER stress (Figure 
4.12).  
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Figure 4.12 Thapsigargin induces hepatocellular ER stress in vitro. Primary mouse 
hepatocytes were treated with titrated doses of thapsigargin for 24 hours. FGF21  was 
then measured in the media. Data are expressed as means ± S.E.M. (n=3 wells/group). 
Significance is indicated *P ≤ 0.05, H2O2 treated group versus corn oil control group 
(Dunnett’s one-way ANOVA). 
 
Muscle myoblast response to hepatocellular damages 
As demonstrated by our in vivo findings (Figure 4.8), liver injury alone or combined with 
diet induced obesity replicated the concomitant muscle atrophy observed in NASH 
patients. Next we queried if the hepatokines generated via the various modes of stress and 
injury would be responsible for the muscle atrophy. In doing so, we took media from our 
various in vitro insults, diluted them (1:10) and placed onto fully differentiated C2C12. 
Myotubes were imaged after 5 days of exposure to insulted hepatocyte media and 
myotube diameter and length were calculated. Treatment with the various challenges 
significantly reduced myotube length as determined by image analysis (Figure 4.13).  
 
47 
 
 
 
Figure 4.13 Inured hepatocyte media reduces myotube diameter in vitro. After 5 days 
of daily exposure to diluted (1:10) injured hepatocyte media, myotube length was 
significantly reduced by CCl4, LPS, and thapsigargin. Data are expressed as means ± 
S.E.M. (n=3 wells/group). Significance is indicated *P ≤ 0.05, treated group versus 
vehicle (corn oil) control group (Dunnett’s one-way ANOVA). 
 
4.3 Activin A and Gdf8 activity in NASH model 
Given the increased signaling of TGFβ superfamily members and their established roles 
in NAFLD and NASH (Polyzos, Kountouras, Anastasilakis, Triantafyllou, & Mantzoros, 
2016), we wanted to evaluate the effects that blocking their signaling in the CCl4 liver 
injury model would have. Neutralization of specific TGFβ superfamily members Activin 
A, Gdf8, and combination of both were compared with the effects of a pan inhibitor 
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soluble decoy receptor Actr2b-Fc. We wanted to simplify our first steps by performing 
our experiments acutely and in lean mice to examine the effects in acute liver injury. 
Antibodies were predosed 24 hours before a single administration of CCl4 in male 
C57BL/6 mice, which were sacrificed after another 24 hours. Predosing regimen was 
chosen to ensure that there was proper exposure of the antibody at the onset of injury. We 
analyzed biochemical assessments of liver injury: ALT, AST levels, total bilirubin, and 
blood glucose. ALT and AST levels were shown to be increased in all CCl4 treatment 
groups, with no significant difference between antibody therapies (Figure 4.14).  
 
 
Figure 4.14 Acute effects of TGFβ family inhibition on liver injury markers. Lean 
male C57BL/6 mice were pretreated with an inhibitor to the TGFβ family, followed by a 
single dose of CCl4 16 hours later. Serum levels of ALT (A) and AST (B) were measured. 
Data are expressed as means ± S.E.M. (n=5 mice/group). Significance is indicated *P ≤ 
0.05, CCl4 treated group versus corn oil control group (Dunnett’s one-way ANOVA). 
 
Additional liver functional markers were measured in serum (bilirubin and glucose) at the 
same time point (Figure 4.15). While CCl4 liver injury increased circulating bilirubin 
levels after a single injection, Gdf8 antibody inhibition statistically improved the buildup 
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of these chemicals. The soluble decoy receptor Actr2b-Fc, which should also inhibit Gdf8 
signaling, improved bilirubin and glucose levels as well. While circulating glucose can 
come from a variety of sources, we know the acute damage to the liver in this model will 
reduce hepatic gluconeogenesis (Carvalho, Jones, McGuirk, Sherry, & Malloy, 2002), 
therefore we measured glucose levels as an analog of this biological function. CCl4 injury 
significantly reduced circulating glucose levels after a single dose. Interestingly, 
inhibition of both Activin A and Gdf8 together slightly protected against this effect. 
Furthermore, the soluble decoy receptor, which inhibits signaling of both proteins, also  
improved circulating glucose levels. An insignificant trend was observed with Gdf8, but a 
noteworthy finding nonetheless.  
 
 
Figure 4.15 Liver function was negatively impacted by CCl4 administration. Lean 
male C57BL/6 mice were pretreated with an inhibitor to the TGFβ family, followed by a 
single dose of CCl4 16 hours later. Blood was then collected 24 hours after the CCl4 dose 
and bilirubin (A) and glucose (B) were measured. Data are expressed as means ± S.E.M. 
(n=5 mice/group). Significance is indicated *P ≤ 0.05, CCl4 treated group versus corn oil 
control group (Dunnett’s one-way ANOVA). 
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Next, gene expression of several members was measured directly in liver tissue. No 
appreciable changes in gene expression of Inhba and Inhbb were noted (data not shown) 
while Gdf8 was mostly below quantifiable limits (data not shown). Intriguingly, 
expression of Gdf15 was attenuated with the combination antibody and ActRIIB-Fc 
treatment (Figure 4.16 A).  Diminished expression of Gdf15 may reflect a dampened 
injury response to CCl4 as it is often correlated with the magnitude of injury. 
 
FGF21 protein levels were also measured in these samples (Figure 4.16 B). Consistent 
with the literature, analysis confirmed increased FGF21 protein levels acutely following 
CCl4 injury. Interestingly, Gdf8 inhibition via its specific antibody increased hepatic 
FGF21 protein, while the pan inhibition via Actr2b-Fc did not. Furthermore, the 
combination of Gdf8 and Activin A neutralization had no effect on hepatic FGF21. 
Increased FGF21 signaling could be a mechanism by which Gdf8 inhibition is protecting 
the liver acutely following injury, and that effect is lost with general blocking of that 
signal through Activin receptor 2 B or Activin A blocking. These data suggest a novel 
role of hepatic Gdf8 signaling in acute CCl4 injury that, when inhibited, appears to illicit 
protective effects on the liver. There is also evidence that if Activin A is neutralized in 
addition to Gdf8, those effects on FGF21 are lost. 
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Figure 4.16 Acute injury increases secondary markers of injury. Lean male C57BL/6 
mice were pretreated with an inhibitor to the TGFβ family, followed by a single dose of 
CCl4 16 hours later. Twenty four hours following the CCl4 injection liver RNA and serum 
was collected. Gene expression and ELISAs performed to measure Gdf15 transcript (A) 
and Fgf21 (B) protein. Gdf15 gene expression was significantly reduced with combined 
inhibition of Gdf8 and Activin A. Liver FGF21 protein was increased by Gdf8 inhibition. 
Data are expressed as means ± S.E.M. (n=5 mice/group). Significance is indicated *P ≤ 
0.05, CCl4 treated group versus IgG control group (Dunnett’s one-way ANOVA). 
 
To confirm if there is any Gdf8 signaling increase in the liver at this 24 timepoint, we 
measured the protein expression both systemically and locally. While circulating Gdf8 
was not increased at this early timepoint (data not shown), there was a considerable 
amount of hepatic Gdf8 protein after CCl4 injury. Gdf8 protein was increased 24 hours 
after a single dose of CCl4, and those protein levels were reduced in all antibody treated 
groups (Figure 4.17 A). Anti-Gdf8 antibodies (including the decoy receptor) will reduce 
and/or sequester Gdf8 protein. However, the reduced hepatic Gdf8 protein following anti-
Activin A treatment was unexpected, and prompted us to measure circulating Activin A 
levels in these animals as well (Figure 4.17 B). Serum Activin A protein levels were 
increased with CCl4 injury after 24 hours, and was reduced with Activin A inhibiting 
antibodies. Unexpectedly, inhibition of Gdf8 caused an increase in circulating Activin A  
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protein levels. This is a novel finding that may suggest a cross regulatory feedback, 
which may have implications in hepatic injury response and disease progression. 
 
 
Figure 4.17 Acute liver injury increases Gdf8 and Activin A protein levels. Lean 
male C57BL/6 mice were pretreated with an inhibitor to the TGFβ family, followed by a 
single dose of CCl4 16 hours later. Twenty four hours following the CCl4 injection liver 
serum was collected and ELISAs performed to measure Gdf8 (A) and Activin A (B) 
protein. Both Activin A and Gdf8 were increased following CCl4 injury. Inhibition of 
Gdf8 increased hepatic Activin A protein beyond levels of CCl4 injury alone. Data are 
expressed as means ± S.E.M. (n=5 mice/group). Significance is indicated *P ≤ 0.05, CCl4 
treated group versus IgG control group (Dunnett’s one-way ANOVA). 
 
In important additional ligand within the TGFβ family that shares a ligand with Activin A 
and Gdf8 is Activin B. We measured serum levels of Activin B in our two hit model, and 
saw increased protein expression in DIO animals, that was increased with the addition of 
CCl4 (Figure 4.18).  
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Figure 4.18 Serum Activin B increases following 4 weeks on DIO+CCl4 NASH 
model. Serum levels of Activin B protein levels were measured and 4 weeks of CCl4 
administration in DIO and lean mice. Activin B was increased by CCl4 treatment 
independent of diet, but significantly higher in DIO+CCl4 after 4 weeks. Data are 
expressed as means ± S.E.M. (n=5 mice/group). Significance is indicated *P ≤ 0.05, 
CCl4-treated group versus corn oil-treated group, † P ≤ 0.05 DIO group versus lean 
control group receiving the same CCl4
 
treatment, for the ELISA (Dunnett’s one-way 
ANOVA). 
 
This increase in Activin B was also observed in another model of liver fibrosis, bile duct 
ligation, in a timecourse study performed in rats (Figure 4.19). Together, these data 
display a conserved role of several TGFβ family members in response to liver injury, 
which could play a significant role in concimitant muscle atrophy. 
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Figure 4.19 Serum Activin B protein is increased following BDL surgery. Serum 
levels of Activin B protein levels were measured in male Sprague dawley rats 4, 6, 11, 
and 15 days after bile duct ligation surgery. Data are expressed as means ± S.E.M. (n=3 
rats/group). Significance is indicated *P ≤ 0.05, compared to the sham surgery at the 
same timepoint for the ELISA (Dunnett’s one-way ANOVA). 
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 DISCUSSION CHAPTER 5.
 
 
 
5.1 Characterization of two-hit in vivo model 
A variety of animal models have been used to replicate NASH pathologies in rodents, 
however a majority of those models are either considerably long in duration, involve 
expensive genetic mutations, or lack specific aspects of the NASH disease state; most 
notably, fibrosis (Hebbard & George, 2011). Carbon tetrachloride (CCl4) is a well 
characterized model of liver injury that quickly generates fibrosis and can eventually lead 
to HCC by inducing centrizonal necrosis via alteration of hepatocellular lysosomal and 
mitochondrial plasma membrane permeability which generates free radical buildup. This 
tissue damage recruits HSCs to proliferate and differentiate into myofibroblast cells that 
deposit ECM and collagen driven by increased TGFβ signaling which leads to 
development of fibrosis (T. Fujii et al., 2010). The use of a high fat diet (HFD) is 
common method of inducing metabolic aspects of NAFLD/NASH (primarily steatosis). 
The combination of the two insults has been suggested to produce pathology similar to 
that of NASH patients in a timely and cost-efficient manner that can elucidate 
mechanisms responsible for fibrosis progression (Kubota et al., 2013). A primary focus 
of our first study was to validate that pathologies associated with human NASH patients 
were presented in our in vivo two-hit model. Measurements of liver function (serum 
bilirubin and glucose) are detrimentally altered after 4 weeks of CCl4 treatment only in 
animals challenged with both hits, suggestive of enhanced liver damage resulting from 
the resident steatosis in HFD animals. Steatosis occurs as a result of triglycerides that 
accumulate in the liver and generate lipotoxicity from elevated levels of free fatty acids, 
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cholesterol, and other lipid metabolites. As a result, inflammatory pathways, ER stress, 
oxidative stress, and ROS stress mechanisms are activated (Cusi, 2009). Our data 
supports the findings that a first hit of steatosis predisposes the animal to pathologies 
resulting from subsequent challenges that increased disease progression. Histological 
analysis of the liver from these animals displayed features characteristic of a NASH 
diagnosis including abundant steatosis, inflammation, hepatocellular ballooning, and 
fibrosis. These findings were supported by an increase in soluble CD14 and 
hepatocellular and circulating FGF21, which were both increased in the combination 
DIO+CCl4 animals. Increases in soluble CD14 levels have been shown to be increased in 
NASH patients, and has been proposed as a biomarker for evaluation of therapeutic 
effects in NAFLD (Ogawa et al., 2013). Studies have demonstrated that FGF21 can 
ameliorate NASH pathologies, and that it plays a significant role in the progression of 
NAFLD (Liu, Xu, Hu, & Wang, 2015). 
 
An unanticipated aspect of the model was an overall loss of adiposity as the study 
progressed, which resulted in a reduction in steatosis by week 4. DIO animals that 
received CCl4 injuries lost approximately 6 gram loss in fat mass (data not shown) after 4 
weeks. While this may ameliorate some of the peripheral metabolic complications 
associated with obesity, it accurately replicates conditions observed in end stage liver 
disease patients. Nayak et al. showed that of 17 NAFLD associated liver transplant 
patients, steatosis was “of the microvascular type and mostly inconspicuous, being 
minimal and mild in 5 and 4 cases respectively; moderate in 4; and marked in only one 
case.” 5 explant samples did not exhibit steatosis at all (Nayak, Vasdev, Saigal, & Soin, 
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2010). Interestingly, one of the most common features observed in these patients was  
nodular and septal inflammation, which was present in all CCl4 livers, and exacerbated 
by a HFD.  
 
While not required for a diagnosis, several studies have shown a strong correlation 
between hepatic fibrosis and the severity and prognosis of NASH. Due to its multifaceted 
pathology, driven primarily through ROS generation, CCl4 has been used as a model to 
induce liver fibrosis for decades. Our studies confirmed the presence of perisinusoidal 
fibrosis in animals injured with CCl4. Unfortunately, while this model has been reported 
to induce severe (bridging) fibrosis in the past (T. Fujii et al., 2010), our studies did not 
replicate the magnitude of in vivo fibrosis observed in cirrhotic or severe NASH patients. 
Bridging fibrosis refers to ECM deposition that reaches from one portal vein to another, 
and its presence is a main factor when considering whether or not a patient requires a 
liver transplant. Due to the high regenerative capacity of rodent livers, it is difficult to 
generate bridging fibrosis in vivo without risking morbidity. Animal studies that have 
been able to generate this severity of fibrosis require 5-6 months of repeated insult. While 
this is potentially an option in lean animals, our studies that applied the combination of a 
HFD and repeated CCl4 injuries leads to liver failure induced morbidity within 6 weeks. 
While analysis of the histology of these animals is still ongoing, a trend in severity of 
peripheral lean mass loss increasing morbidity of these animals was clear. Therefore, 
applications of this model to include metabolic syndrome are too severe to generate the 
most robust amounts of hepatic fibrosis. The resident conditions associated with obesity 
present in our two-hit model appear to enhance the morbidity of liver disease, and should  
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be considered a model of end stage liver failure more than NAFLD to mild NASH 
pathology.  
 
The resident conditions associated with an obese state in this model (heightened 
inflammatory state, lipotoxicity, and hyperglycemia) were shown to increase mortality of 
rodents challenged with CCl4 after 4 weeks. While these conditions were enough to be 
deleterious to liver injury survival outcomes, they are not entirely representative of the 
entire spectrum of metabolic complications present in diabetic patients. DIO animals fed 
a high fat chow are a accurate model of obesity that reflects many of the complications 
associated with T2DM, but not necessarily a Frank diabetic. DIO animals are typically 
mildly insulin resistant and do not display the full extent of insulin resistance or beta cell 
failure present in an obese diabetic individual. A potential consideration for future studies 
would be to include additional dietary insults (i.e. cholesterol or fructose) or utilize 
genetic modification (i.e. db/db or ob/ob mice) to exacerbate metabolic complications in 
these animals. Most importantly, after repeated administrations of CCl4, these animals 
begin to lose their obese state. After the first few doses, the initial body weight loss can 
be partially attributed to a food intake reduction. However, as the model progresses, food 
intake recovers to normal rates (data not shown), but fat mass loss is still observed. This 
phenomenon is most likely caused by reduced hepatobiliary function resulting from 
inflammation and fibrosis limiting hepatic vascular flow. Importantly, body weight loss is 
seen in end stage liver disease patients, and can sometimes be recovered following 
transplant (Nishikawa & Osaki, 2015). 
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A contributing factor to the loss in body weight of end stage liver disease patients is a 
loss of muscle mass (Plank & Russell, 2015). The contributions of concomitant 
sarcopenia to disease pathology and survival outcomes in these patients are just now 
beginning to be studied, and  the evidence shows a positive correlation between disease 
prognosis and lean mass (Carias et al., 2016). While the molecular relationship between 
liver disease and sarcopenia is not well understood, it is clear that the pro-regenerative 
capacities of both tissues (liver and muscle) share are very similar mechanisms of repair. 
Previous studies demonstrated that liver injury via CCl4 reduced the capacity for muscle 
to regenerate following cardiotoxin induced injury, and was ameliorated by inhibiting 
TGFβ family members signaling through use of a pan inhibitor. Yaden et al.’s data 
suggests a similar role for TGFβ family signaling in both liver and muscle regeneration. 
Our data demonstrated an increase of hepatic signaling of TGFβ members Activin A and 
B (Chen et al., 2014) and Gdf8 (Nissinen et al., 2016) that are known to contribute to 
muscle atrophy. Therefore, we hypothesized that the CCl4 dependent increase in hepatic 
Gdf8 and two-hit dependent increase in Activin expression contribute to concomitant 
muscle atrophy. The observation of a loss of lean mass was a key finding in our studies. 
Evidence suggests in vivo replication of liver disease induced sarcopenia is an important 
component to the pathology of the disease with a strong correlation to fibrosis severity 
(Koo et al., 2016).  
 
5.2 TGFβ sgnaling in two-hit model 
It has been well established that TGFβ (Sakai, Jawaid, Sasaki, Bou-Gharios, & Sakai, 
2014) and Activin A (Palin et al., 2016)  regulate various types of liver disease 
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progression. Specifically, Activin A levels have been shown to be increased in NASH 
patients (Polyzos et al., 2016), while TGFβ is considered to be a potent regulator of 
fibrosis in the liver and other tissues (Montano-Loza, Thandassery, & Czaja, 2016). We 
confirmed increased hepatic expression of these factors in our model, but were also 
interested in other members of this family. Most notably, increased hepatic expression of 
the well described myokine Gdf8 is a novel finding in this model. Very little is known 
about the role of Gdf8 in liver injury response. One study showed that reduced myostatin 
signaling protected against diet induced hepatosteatosis (Guo, Wong, & Bhasin, 2013). 
Role of another TGFβ member, Activin B, in liver disease is well characterized pro-
inflammatory agent (Canali et al., 2016). Until recently a lack of a specific detection 
antibody has limited efforts to investigate its response at a protein level in various 
models. Interestingly, our model shows an increase in Activin B (Figure 4.18). The 
primary focus for the past few decades has been on Activin A, this regulation of Activin 
B provides another integral playe rin th epathogenesis or progressin of disease. Further 
studies should focus on the novel role of Activin B and its interplay with other TGFβ 
superfamily proteins in hepatocellular injury repair and disease progression, as it appears 
to represent an un researched potential therapeutic opportunity. 
 
5.3 In vitro replication of concomitant muscle atrophy 
In order to better understand the role individual pathologies associated with liver injury 
have on muscle atrophy, we attempted to recreate the in vivo challenges of our model in 
an in vitro setting. As the data demonstrated, aspects of ER stress and ROS generation 
were sufficient to induce hepatocellular injury as measured by ALT/AST levels in the 
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media. In vitro hepatocellular injury was sufficient to reduce myotube diameter when 
placed on C2C12 muscle myoblasts. This data demonstrates that a variety of models of 
liver injury are capable eliciting direct negative effects on myotube health. Trendelenburg 
et al. showed that Activins and Gdf8 reduce myotube diameter and differentiation 
(Trendelenburg et al., 2009). Our findings demonstrated that myotube size reduction 
could potentially be indued by TGFβ members of hepatocyte origin, and can be 
ameliorated with addition of inhibiting antibodies. Followup studies are underway to 
evaluate hepatocelluar TGFβ family signalling following in vitro insult by measuring 
Activin, Gdf8, and TGFβ content in the media. Additionally, we intend to measure 
downstream Smad2/3 signaling in myotubes, which would indicate a direct role of TGFβ 
family signaling in myotube response to the injured hepatocyte media. An important 
caveat worth considering in this experiment is that the myotube media contains diluted 
chemical toxins used to insult the hepatocytes. This was controlled by adding CCl4 alone 
into media without hepatocellular media to myotubes at equivalent concentrations (data 
not shown). While our AST/ALT data suggest that a 1:10 dilution shifts the concentration 
below the level of inducing injury, there is a risk that the presence of these chemicals is 
affecting the myotubes. In order to account for this, we attempted to separate the media 
containing hepatotoxins from those placed on the myotubes. Hepatocytes were injured 
with CCl4 for 6 hours, media was removed, and fresh media lacking hepatotoxins was 
added. ALT/AST measurements 18 hours later showed no ALT/AST increases (data not 
shown). This suggests the initial 6 hour window is when hepatocellular damage takes 
place, or the hepatocytes are able to recover sufficiently with 18 hours removed from  
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insult. More work is required to determine a method for adding hepatocyte media to 
myotubes without also including the diluted hepatotoxin. 
 
5.4 Inhibition of TGFβ members in two-hit model 
Our studies showed that the two-hit model exhibited pathologies characteristic to NASH 
patients that drive concomitant muscle atrophy possibly driven by TGFβ superfamily 
signaling. In order to evaluate the effects of this proteins on liver and muscle pathology, 
we inhibited their function via antibody treatment in vivo. In lean animals, DIO+CCl4 
animals treated with combination Gdf8 and Activin A antibodies appeared to be protected 
from hepatic damage. Interstingly, a novel increase in circulating Activin A (more than 
two-fold greater than CCl4 alone) was observed in animals treated with anti Gdf8 
antibody along with CCl4 injury. Abnormal Activin A expression is related to a variety of 
diseases and play an important role in acute hepatic injury response (Wang et al., 2013). 
Furthermore, Activin A inhibiting antibody reduced hepatic induction of Gdf8 following 
injury. Increased protein expression of Activin A by inhibiting Gdf8 and decresaed Gdf8 
expression by inhibiting Activin A suggests a novel regulatory feedback system within 
the TGFβ supefamily that regulates signifcant aspects of injury response. This type of 
autoregulatory system within the family is not a novel finding. Activin A has been shown 
to regulate its inhibitor FST (Kipp et al., 2011), and conversely FST has been shown to 
upregulate Gdf8 expression as well (Kocamiş, Gulmez, Aslan, & Nazli, 2004). Our data 
suggests the discovery of a possible direct Gdf8 Activin A autoregulatory system. To this 
end, the source of additional Activin A will be of primary interest in future studies. 
Currently, RNA expression analysis of muscle and liver have shown no increases in 
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inhba expression (data not shown). Analysis of various potential sources (whole blood, 
testes, and hypothalamus) of Activin A are currently being investigated for transcriptional 
upregulation. 
 
An important aspect of our in vivo model includes the concimitant muscle atrophy 
observed in NASH and end stage liver disease patients. TGFβ superfamily members 
Gdf8 and Activins are known to negatively effect muscle growth and regeneration. 
Specific inhibition of Gdf8 protected against lean mass loss, while blocking of Activin A 
signaling has no effect in DIO animals injured with CCl4 for 5 weeks. Interestingly, pan 
inhibition of signaling via Actr2b-Fc antibody treatment significantly increased lean mass 
compared to animals that did not receive doses of CCl4. This is a novel discovery of a 
potential additional ligand of the Activin 2b receptor that contributes to enhanced muscle 
pathology in liver disease. While inhibiting Activin A and Gdf8 provide protection from 
muscle wasting, that therapeutic approach seemingly fails to account for Activin B, 
which shows potential for its own role in NASH and its concomitant muscle atrophy. 
Potential therapies should consider this additional effector in impacting muscle health. 
This data strongly suggests another ligand for this receptor that is having a deleterious 
effect on muscle mass in our two-hit model. A proposed candidate that could be 
responsible for this effect is Activin B. Activin B is a ligand for the Actr2b receptor, and 
genetic inhibition of Activin B is known to increase muscle mass (Chen et al., 2015). 
Activin B protein levels were measured in our two hit model, and was shown to be 
increased with added challenges (Figure 4.18). 
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An important validation of this finding was to investigate that Activin B signaling is 
increased in other models of liver injury. Bile duct ligation is a surival surgery that blocks 
the extrahepatic biliary system which initiates a cascade of pathological outcomes 
resulting in cholestasis and inflammation. This injury eventually generates substantial 
fibrosis (Tag et al., 2015). Serum from a timecourse bile duct ligation clearly 
demonstrated a time dependent increase in circulating Activin B protein (Figure 4.19). 
 
Antibodies targeted at pan inhibition of TGFβ family signaling have shown to be an 
effective treatment for muscle atrophy (Lach-Trifilieff et al., 2014), while Gdf8 specific 
antibodies have not proven to be quite as effective (Becker et al., 2015). Our studies show 
that Activin signaling could be a contributing factor to the increased efficacy of a pan 
inhibitor decoy receptor based approaches by inhibiting signaling of additional (I assume) 
ligands responsible for muscle atrophy. Gdf8 inhibition induced increase in Activin A 
protein could lead to reduced muscle health and function (Yaden et al., 2014). While 
increases in Activin B, which would be sequestered by a decoy receptor, observed in liver 
disease patients may contribute to increased skeletal muscle atrophy. Future studies to 
explore the regulatory feedback of Activin A and myostatin are required to evaluate the 
potential effects increased Activin A is having on the liver and muscles in this model. 
Also, hepatic and muscle effects of Activin B inhibition in models of liver disease have 
not yet been published. Additional analysis of this promising aspect of sarcopenia therapy 
are of particular interest moving forward. 
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5.5 Conclusions 
Concomitant sarcopenia is beginning to emerge as an important pathology associated 
with liver disease patient outcome. Given the unmet medical need associated with NASH 
patients related to the growing obesity epidemic, a reliable and cost effective in vivo 
model is critically important. The potential impact on patient health makes it important to 
evaluate all underlying aspects of the disease when considering underlying mechanisms 
of disease progression and potential therapies. New data suggests a novel role of TGFβ 
family members Gdf8 and Activin B in NASH associated sarcopenia, providing potential  
utility for existing therapies which target pan inhibition of their receptor. In summary,  
these data highlight the important connection between liver disease and muscle atrophy 
with a specific role for the highly conserved TGFβ superfamily in these disease states. 
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